Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · Real-Time Price · USD

22.72

+0.89 (4.08%)

At close: Feb 20, 2026, 4:00 PM EST

22.28

-0.44 (-1.94%)

After-hours: Feb 20, 2026, 7:20 PM EST

Ultragenyx Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	673	560.23	434.25	363.33	351.41
Revenue Growth (YoY)	20.13%	29.01%	19.52%	3.39%	29.66%
Cost of Revenue	859	774.59	693.66	734.11	513.16
Gross Profit	-186	-214.36	-259.41	-370.78	-161.76
Selling, General & Admin	349	321.61	309.8	278.14	219.98
Operating Expenses	349	321.61	309.8	278.14	219.98
Operating Income	-535	-535.97	-569.21	-648.92	-381.74
Interest Expense	-62	-63.04	-66	-43.02	-29.42
Interest & Investment Income	-	36.51	26.69	11.07	1.93
Other Non Operating Income (Expenses)	26	-3.96	-0.34	-1.57	-1.69
EBT Excluding Unusual Items	-571	-566.47	-608.86	-682.43	-410.92
Gain (Loss) on Sale of Investments	-	-1.12	0.4	-19.3	-42.06
Pretax Income	-571	-567.59	-608.46	-701.73	-452.98
Income Tax Expense	4	1.6	-1.83	5.7	1.04
Net Income	-575	-569.18	-606.64	-707.42	-454.03
Net Income to Common	-575	-569.18	-606.64	-707.42	-454.03
Shares Outstanding (Basic)	99	91	74	70	68
Shares Outstanding (Diluted)	99	91	74	70	68
Shares Change (YoY)	8.90%	23.11%	5.19%	3.13%	11.42%
EPS (Basic)	-5.83	-6.29	-8.25	-10.12	-6.70
EPS (Diluted)	-5.83	-6.29	-8.25	-10.12	-6.70
Free Cash Flow	-	-421.68	-519.07	-496.59	-411.79
Free Cash Flow Per Share	-	-4.66	-7.06	-7.10	-6.07
Gross Margin	-27.64%	-38.26%	-59.74%	-102.05%	-46.03%
Operating Margin	-79.50%	-95.67%	-131.08%	-178.60%	-108.63%
Profit Margin	-85.44%	-101.60%	-139.70%	-194.70%	-129.20%
Free Cash Flow Margin	-	-75.27%	-119.53%	-136.68%	-117.18%
EBITDA	-500.05	-500.43	-543.2	-630.7	-368.5
EBITDA Margin	-74.30%	-89.33%	-125.09%	-173.59%	-104.86%
D&A For EBITDA	34.95	35.54	26.01	18.22	13.24
EBIT	-535	-535.97	-569.21	-648.92	-381.74
EBIT Margin	-79.50%	-95.67%	-131.08%	-178.60%	-108.63%
Revenue as Reported	673	560.23	434.25	363.33	351.41

Updated Feb 12, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q